Wednesday, June 13, 2012

Advaxis, Inc. (ADXS) Announces Publication of Positive Results for Prostate Cancer Immunotherapy Study

Advaxis, clinical-stage developer of next-generation immunotherapies for cancer and infectious diseases, today announced the publication of research with the company’s ADXS-PSA (ADXS31-142), which demonstrated significant tumor regression in prostate cancer in preclinical study.

The study was conducted to determine if the combination of ADXS-PSA immunotherapy and radiation therapy could improve upon the efficacy of either immunotherapy as stand-alone treatment or radiation therapy as a stand-alone in the treatment of mice bearing PSA-expressing TPSA23 tumors, a preclinical model of prostate cancer.

The study showed that the combination of ADXS-PSA immunotherapy and radiation therapy resulted in complete regression of established tumors in 60 percent of mice vs. 10 percent complete regression in either of the treatments alone.

This research was conducted in collaboration with Dr. Chandan Guha and his laboratory at Montefiore Medical Center, Bronx, NY, and was e-published ahead of print in the journal of Cancer Immunology Immunotherapy in the paper titled “Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer.”

“ADXS-PSA continues to demonstrate activity in models of prostate cancer, confirming our decision to move this construct into clinical development. The potential synergy of ADXS-PSA and radiotherapy observed in this study suggests that ADXS-PSA might be combined with other therapies that show efficacy in this type of tumor,” Dr. John Rothman, EVP of Science and Operations at Advaxis stated in the press release.

For more information visit www.advaxis.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

No comments: